Previous 10 | Next 10 |
Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) this morning announced that it has retained the services of leading pharmaceutical branding agency, Addison Whitney, representing the next step toward commercialization of its lead drug candidate. Utilizing its 28-year history, Addi...
Genprex takes next steps toward identifying drug name for future commercialization Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the service...
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full pu...
NetworkNewsWire Editorial Coverage : Gene therapies are gaining growing attention within the medical sector. Gene therapies help restore or replace the body’s damaged or missing genes. Groundbreaking treatments can stop the spread of cancer cells, cause cancer cells to die. G...
Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) recently reported that positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody was recorded by its University of Texas MD Anderson Cancer Center collaborators in a lung cancer treatment study ( http...
NGM Biopharmaceuticals (NASDAQ: NGM ) initiated with Buy rating $29 (85% upside) price target at Citigroup. Initiated with Outperform rating and $25 price target at Cowen. Initiated with Buy rating and $22 price target at Goldman Sachs. More news on: NGM Biopharmaceuticals, Inc., Silk Road...
Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) is focused on the development of potentially life-changing technologies for cancer patients. A recent article discussing GNPX reads, “Genprex holds a portfolio of 30 issued and two pending patents covering its technologies an...
Genprex’s collaborators at MD Anderson reported positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody for the treatment of non-small cell lung cancer The TUSC2 gene, a tumor suppressor gene, is the active agent in Genprex’s Oncoprex immuno...
Clinical-stage gene-therapy company Genprex (NASDAQ: GNPX) is at the forefront to advance innovative developments in the war against lung cancers, testing its trademarked Oncoprex immunogene therapy. A recent article discussing this reads, “Oncoprex’s phase I and II clinical-st...
New York, New York--(Newsfile Corp. - April 12, 2019) - Genprex Inc. (NASDAQ: GNPX) announces the availability of a NetworkNewsAudio broadcast titled, " Potential Blockbuster Gene Therapy Programs to Watch in 2019 ." To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/j1WMs ...
News, Short Squeeze, Breakout and More Instantly...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024 Acclaim-3 Study Suppor...